Research
Hormonal
GLP-1RAs may lead to treatment discontinuation due to gastrointestinal side effects.
Clinicians should prepare patients for the possibility of discontinuation due to side effects.
StrongSupportsmedium confidence
Common side effects... potentially resulting in treatment discontinuation.
Why this rating
The abstract discusses the impact of side effects on treatment adherence.
Source
Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions
Alaa Ismail et al. · World Journal of Gastrointestinal Pharmacology and Therapeutics · 2025
DOI 10.4292/wjgpt.v16.i3.107148
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →